Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP).

PURPOSE To correlate targeting deviation in external beam radiation therapy with site of relapse in a prospective study of 174 patients treated for medulloblastoma. METHODS AND MATERIALS Between February 1992 and February 1998 the radiotherapy treatment records were reviewed by a panel of radiation oncologists for 174 children treated with radiation therapy for medulloblastoma. The review was done without knowledge of patient outcome. Patterns of relapse were correlated with the results of the quality control review. RESULTS Among the 174 patients five relapsed before the start of radiotherapy. One hundred sixty-nine patients were evaluable for correlation between targeting deviation and site of relapse. Number of major deviations in radiation therapy treatment is strongly correlated with the risk of tumor relapse (67% [95% CI: 28-91] of 3-year relapse rate in patient group with 2 major deviations and 78% [95% CI: 35-96] with 3 major deviations). This is particularly correlated with relapse in the frontal region of the brain: 5 relapses occurred in the frontal region in patients with major deviation in this area. An erroneous choice of electron beam energy is also linked with craniospinal fluid (CSF) relapse (3-year relapse rate of 68% [95% CI: 42-86]). Minor deviations in therapy technique are slightly associated with an increased risk of relapse in the same range as the group with only one major deviation. CONCLUSION The quality of medulloblastoma radiation therapy technique is strongly correlated with outcome. Pretreatment central quality assurance review or standardized computer-designed blocks would improve survival to an extent equivalent to that attributed to adjuvant chemotherapy.

[1]  J. Lagrange,et al.  Quality control of radiotherapeutic treatment of medulloblastoma in a multicentric study: the contribution of radiotherapy technique to tumour relapse. The French Medulloblastoma Group. , 1992, Radiotherapy and Oncology.

[2]  M. Chen,et al.  Adjuvant chemotherapy for medulloblastoma , 1985, Cancer.

[3]  W. Wara,et al.  Low-dose craniospinal radiation therapy for medulloblastoma. , 1991, International journal of radiation oncology, biology, physics.

[4]  L. Marks,et al.  Defining the superior border of posterior fossa radiation treatment fields. , 1998, International journal of radiation oncology, biology, physics.

[5]  G. Grabenbauer,et al.  Postoperative radiotherapy of medulloblastoma. Impact of radiation quality on treatment outcome. , 1996, American journal of clinical oncology.

[6]  H. Bloom,et al.  Adjuvant chemotherapy for medulloblastoma: the first multi-centre control trial of the International Society of Paediatric Oncology (SIOP I). , 1990, European journal of cancer.

[7]  E. Halperin,et al.  Medulloblastoma: the Duke University Medical Center experience. , 1986, International journal of radiation oncology, biology, physics.

[8]  W. Wara,et al.  The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. , 1990, Journal of neurosurgery.

[9]  H. Friedman,et al.  Subfrontal recurrence of medulloblastoma. , 1992, AJNR. American journal of neuroradiology.

[10]  W. Winkelmann,et al.  Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. , 1995, International journal of radiation oncology, biology, physics.